NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: G
Post# of 231
(Total Views: 391)
Posted On: 03/05/2020 3:39:19 PM
NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Lead Researcher Behind its Diabetes Gene Therapy Featured in New Video Interview
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy. According to the update, Dr. Gittes joined one of Proactive’s broadcast journalists to provide an overview of the gene therapy, how it works, how it may have the potential to help treat type 1 and type 2 diabetes, as well as next steps to move the gene therapy to the clinic. “We noticed that by gene therapy we could cause some of the cells in the pancreas that do not normally make insulin, but they are closely related to insulin cells, to turn into an insulin-producing cell,” Dr. Gittes, Co-Scientific Director and Professor of Surgery at the UPMC Children’s Hospital of Pittsburgh, said in the interview. “The real excitement came when we realized that when we did this in a mouse that normally reacts to its own insulin cells in the same way a juvenile diabetic or Type 1 diabetic does, it didn’t notice these [new] cells and left them alone for a long time without us doing anything else. It was just one treatment with a gene therapy, and they [the mice] were fine for months, which is exciting.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy. According to the update, Dr. Gittes joined one of Proactive’s broadcast journalists to provide an overview of the gene therapy, how it works, how it may have the potential to help treat type 1 and type 2 diabetes, as well as next steps to move the gene therapy to the clinic. “We noticed that by gene therapy we could cause some of the cells in the pancreas that do not normally make insulin, but they are closely related to insulin cells, to turn into an insulin-producing cell,” Dr. Gittes, Co-Scientific Director and Professor of Surgery at the UPMC Children’s Hospital of Pittsburgh, said in the interview. “The real excitement came when we realized that when we did this in a mouse that normally reacts to its own insulin cells in the same way a juvenile diabetic or Type 1 diabetic does, it didn’t notice these [new] cells and left them alone for a long time without us doing anything else. It was just one treatment with a gene therapy, and they [the mice] were fine for months, which is exciting.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)